Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 13/20 | 0.61 |
| ▸ | PDE4A | P27815 | 8/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446266 | 0.88 | TNF (0.65) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7448361 | 0.82 | MEN1 (0.63) | TNFMEN1KMT2A | |
| SCHEMBL7441945 | 0.77 | TNF (0.74) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10323080 | 0.76 | TNF (0.62) | TNFMEN1KMT2A | |
| SCHEMBL10323079 | 0.76 | TNF (0.62) | TNFMEN1KMT2A | |
| SCHEMBL825484 | 0.76 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7445922 | 0.74 | TNF (0.84) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7439026 | 0.73 | TNF (0.53) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8779393 | 0.72 | CYP1A2 (0.37) | TNF | |
| SCHEMBL16692506 | 0.71 | TNF (0.50) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0797437-B1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNFalpha | CELGENE CORP (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0942902-A2 | NOVEL IMMUNOTHERAPEUTIC IMIDES/AMIDES | CELGENE CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998024763-A2 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AS PDE IV AND TNF INHIBITORS | CELGENE CORPORATION (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5703098-A | INHIBITORS OF CYTOKINES INCLUDING TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0797437-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996020705-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |